The Patent Finder

Maintenance fees coming due

Dyne Therapeutics, Inc.

13 maintenance fees come due in the 12 months from Nov 19, 2026, the next on Dec 13, 2026. Unpaid by Jun 14, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 11,672,872Anti-Transferrin Receptor Antibody and Uses Thereof
In force
Fee due Dec 13, 2026
Lapses if unpaid Jun 14, 2027
 · High confidence
Dyne Therapeutics, Inc.In forceDec 13, 2026Jun 14, 2027High confidence
US 11,679,161Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
Fee due Dec 20, 2026
Lapses if unpaid Jun 21, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceDec 20, 2026Jun 21, 2027Medium confidence
US 11,759,525Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
Fee due Mar 19, 2027
Lapses if unpaid Sep 20, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceMar 19, 2027Sep 20, 2027Medium confidence
US 11,771,776Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
Fee due Apr 3, 2027
Lapses if unpaid Oct 4, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceApr 3, 2027Oct 4, 2027Medium confidence
US 11,787,869Methods of Using Muscle Targeting Complexes to Deliver an Oligonucleotide to a Subject Having Facioscapulohumeral Muscular Dystrophy or a Disease Associated with Muscle Weakness
In force
Fee due Apr 17, 2027
Lapses if unpaid Oct 18, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceApr 17, 2027Oct 18, 2027Medium confidence
US 11,795,233Muscle-Targeting Complex Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
In force
Fee due Apr 24, 2027
Lapses if unpaid Oct 25, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceApr 24, 2027Oct 25, 2027Medium confidence
US 11,795,234Methods of Producing Muscle-Targeting Complexes Comprising an Anti-Transferrin Receptor Antibody Linked to an Oligonucleotide
In force
Fee due Apr 24, 2027
Lapses if unpaid Oct 25, 2027
 · Low confidence
Dyne Therapeutics, Inc.In forceApr 24, 2027Oct 25, 2027Low confidence
US 11,833,217Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
Fee due Jun 5, 2027
Lapses if unpaid Dec 6, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceJun 5, 2027Dec 6, 2027Medium confidence
US 11,839,660Anti-Transferrin Receptor Antibody and Uses Thereof
In force
Fee due Jun 12, 2027
Lapses if unpaid Dec 13, 2027
 · High confidence
Dyne Therapeutics, Inc.In forceJun 12, 2027Dec 13, 2027High confidence
US 11,844,843Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
Fee due Jun 19, 2027
Lapses if unpaid Dec 20, 2027
 · Medium confidence
Dyne Therapeutics, Inc.In forceJun 19, 2027Dec 20, 2027Medium confidence
3 more maintenance fees coming due in the 12 months from Nov 19, 2026 · Pro
10 of 13 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Upgrade to Pro
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited